AtriCure (ATRC) Projected to Post Quarterly Earnings on Thursday

AtriCure (NASDAQ:ATRC) is expected to announce its earnings results after the market closes on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

AtriCure Trading Down 6.6 %

NASDAQ ATRC opened at $38.22 on Wednesday. The company has a quick ratio of 2.59, a current ratio of 3.62 and a debt-to-equity ratio of 0.13. AtriCure has a twelve month low of $18.94 and a twelve month high of $43.11. The firm has a market capitalization of $1.86 billion, a PE ratio of -46.05 and a beta of 1.46. The stock’s 50 day moving average is $35.90 and its 200 day moving average is $31.64.

Analysts Set New Price Targets

ATRC has been the topic of several research reports. Needham & Company LLC restated a “buy” rating and set a $51.00 price target on shares of AtriCure in a research report on Thursday, February 13th. Piper Sandler boosted their target price on AtriCure from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Oppenheimer upped their price target on AtriCure from $36.00 to $45.00 and gave the company an “outperform” rating in a report on Thursday, February 13th. Canaccord Genuity Group upped their price target on AtriCure from $61.00 to $66.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Finally, JMP Securities reiterated a “market outperform” rating and set a $60.00 price objective on shares of AtriCure in a research report on Monday, February 10th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, AtriCure currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.56.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.